Pazopanib

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Pazopanib
Pazopanib.svg
Pazopanib3Dan.gif
Systematic (IUPAC) name
5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzolsulfonamide
Clinical data
Trade names Votrient
AHFS/Drugs.com monograph
MedlinePlus a610013
Licence data EMA:Link, US FDA:link
Pregnancy cat. D (AU) D (US)
Legal status Prescription Only (S4) (AU) -only (CA) POM (UK) -only (US)
Routes Oral
Pharmacokinetic data
Protein binding >99%[1]
Metabolism Hepatic (CYP3A4, 1A2 and 2C8-mediated)[1]
Half-life 31.9 hours[1]
Excretion Faeces (primary), urine (<4%)[1]
Identifiers
CAS number 444731-52-6 N
ATC code L01XE11
PubChem CID 11525740
ChemSpider 9700526 YesY
UNII 7RN5DR86CK YesY
ChEMBL CHEMBL477772 N
Chemical data
Formula C21H23N7O2S 
Mol. mass 437.517 g/mol
 N (what is this?)  (verify)

Pazopanib (trade name Votrient) is a potent and selective multi-targeted receptor tyrosine kinase inhibitor that blocks tumour growth and inhibits angiogenesis. It has been approved for renal cell carcinoma and soft tissue sarcoma by numerous regulatory administrations worldwide.[2][3][4][5]

Medical uses[edit]

It is approved by numerous regulatory administrations worldwide (including the FDA (19 October 2009), EMA (14 June 2010), MHRA (14 June 2010) and TGA (30 June 2010)) for use as a treatment for advanced/metastatic renal cell carcinoma and advanced soft tissue sarcomas.[1][2][3][4][5] In Australia it is subsidised under the PBS, under a number of conditions, including:[6]

  • The medication is used to treat clear cell variant renal cell carcinoma.
  • The treatment phase is continuing treatment beyond 3-months.
  • The patient has been issued an authority prescription for pazopanib
  • The patient must have stable or responding disease according to the Response Evaluation Criteria In Solid Tumours (RECIST)
  • This treatment must be the sole tyrosine kinase inhibitor subsidised for this condition.

It has also demonstrated initial therapeutic properties in patients with ovarian and non-small cell lung cancer,[7] though plans to apply to the EMA for a variation to include advanced ovarian cancer have been withdrawn and a license will not be sought in any country.[8][9]

Adverse effects[edit]

Adverse effects by frequency:[1][2][3][4][5][10]

Very common (>10% frequency):

Common (1-10% frequency):

Uncommon (0.1-1% frequency):

  • Torsades de pointes
  • Heart failure
  • Liver failure
  • GI perforation (may be fatal)
  • Fistula formation

Rare (<0.1% frequency):

  • Reversible posterior leucoencephalopathy syndrome

Denotes side effects seen at the above frequency only in clinical trials performed in people with renal cell carcinoma. Denotes side effects seen at the above frequency only in clinical trials done in people with soft tissue sarcomas.

Notes

  1. ^ Usually occurs within the first 18 weeks of treatment. 39% of cases develop within the first 9 days of treatment
  2. ^ This includes leucopenia, thrombocytopenia and neutropenia
  3. ^ This includes leucopenia, lymphopenia, thrombocytopenia and neutropenia


Summary
The most common side effects of pazopanib are nausea, vomiting, diarrhoea (occurs in about half of patients), changes in hair colour, hypertension (which usually occurs during the first few weeks of treatment), appetite loss, hyperglycaemia, hypoglycaemia, electrolyte abnormalities (including hypocalcaemia, hypomagnesemia, hypophosphatemia), lab anomalies (including increased AST, ALT and protein in the urine), oedema, hair loss or discolouration, taste changes, abdominal pain, hypertension, rash, fatigue and myelosuppression (including leucopenia, neutropenia, thrombocytopenia and lymphopenia).[11] It has been associated with a low, but real risk of potentially fatal liver damage.[11]

Contraindications[edit]

The only contraindication is hypersensitivity to pazopanib or any of its excipients.[4] Cautions include:[1]

It has one black box warning by the US FDA, severe hepatotoxicity, including fatalities.[1]

Interactions[edit]

Drug interactions include:[1]

Overdose[edit]

The treatment for overdose is purely supportive and the symptoms include grade 3 hypertension and fatigue.[4]

Mechanism of action[edit]

It is a multikinase inhibitor, with c-KIT, FGFR, PDGFR and VEGFR being amongst the inhibited enzymes.[1][11][12][13][14]

References[edit]

  1. ^ a b c d e f g h i j "Votrient (pazopanib) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Retrieved 27 January 2014. 
  2. ^ a b c "VOTRIENT (pazopanib hydrochloride) tablet, film coated [GlaxoSmithKline LLC]" (PDF). DailyMed. GlaxoSmithKline LLC. November 2013. Retrieved 27 January 2014. 
  3. ^ a b c "Votrient : EPAR - Product Information" (PDF). European Medicines Agency. Glaxo Group Ltd. 23 January 2014. Retrieved 27 January 2014. 
  4. ^ a b c d e "Votrient 200 mg and 400 mg film coated tablets - Summary of Product Characteristics (SPC)". electronic Medicines Compendium. GlaxoSmithKline UK. 20 December 2013. Retrieved 27 January 2014. 
  5. ^ a b c "PRODUCT INFORMATION VOTRIENT® TABLETS" (PDF). TGA eBusiness Services. GlaxoSmithKline Australia Pty Ltd. 25 March 2013. Retrieved 27 January 2014. 
  6. ^ "Pharmaceutical Benefits Scheme (PBS) - Pazopanib". Pharmaceutical Benefits Scheme. Australian Government. Retrieved 27 January 2014. 
  7. ^ "Pazopanib shows encouraging activity in several tumour types, including soft tissue sarcoma and ovarian cancer". FierceBiotech. 2008-09-15. Retrieved 2010-08-10. 
  8. ^ "GSK pulls bid to extend use of kidney drug to ovarian cancer". Reuters. 31 March 2014. Retrieved 7 April 2014. 
  9. ^ "Regulatory update: Votrient® (pazopanib) as maintenance therapy for advanced ovarian cancer in the EU". GlaxoSmithKline. 31 March 2014. Retrieved 7 April 2014. 
  10. ^ Rossi, S, ed. (2013). Australian Medicines Handbook (2013 ed.). Adelaide: The Australian Medicines Handbook Unit Trust. ISBN 978-0-9805790-9-3.  edit
  11. ^ a b c Zivi, A; Cerbone, L; Recine, F; Sternberg, CN (September 2012). "Safety and tolerability of pazopanib in the treatment of renal cell carcinoma". Expert Opinion on Drug Safety 11 (5): 851–859. doi:10.1517/14740338.2012.712108. PMID 22861374. 
  12. ^ Verweij, J; Sleijfer, S (May 2013). "Pazopanib, a new therapy for metastatic soft tissue sarcoma". Expert Opinion on Pharmacotherapy 14 (7): 929–935. doi:10.1517/14656566.2013.780030. PMID 23488774. 
  13. ^ Schöffski, P (June 2012). "Pazopanib in the treatment of soft tissue sarcoma". Expert Review of Anticancer Therapy 12 (6): 711–723. doi:10.1586/era.12.41. PMID 22716487. 
  14. ^ Pick, AM; Nystrom, KK (March 2012). "Pazopanib for the treatment of metastatic renal cell carcinoma". Clinical Therapeutics 34 (3): 511–520. doi:10.1016/j.clinthera.2012.01.014. PMID 22341567.